Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Celcuity (CELC) will feature four gedatolisib presentations at the ESMO Congress, held October 23–27, 2026, in Madrid, Spain.

Rhea-AI Summary

Celcuity (CELC) will feature four gedatolisib presentations at the ESMO Congress, held October 23–27, 2026, in Madrid, Spain. The program includes a late-breaking rapid oral presentation on October 24 covering updated Phase 3 VIKTORIA-1 results, including additional subgroup analyses from the PIK3CA mutant-type breast cancer cohort.

Three posters cover a comparative analysis of the VIKTORIA-1 PIK3CA wild-type cohort against other breast cancer regimens, gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer, and the Phase 3 VIKTORIA-2 first-line breast cancer study. Abstracts will be published on the ESMO website on October 19, 2026.

Argus 15 min delay 3 alerts

-3.68% vs previous close $69.45 last price 1.9x rel. volume Open Argus

Details

Market move: CELC -3.68% vs previous close. ESMO presentation schedule

$68.50 – $76.00 Day Range

$3.40B Market Cap

On Oct 5, the day this news came out, the latest delayed price for CELC is 3.68% below the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $69.45. Relative volume is above average at 1.9x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

mcrpc, pik3ca, her2-, hr+

4 terms

mcrpc medical

"metastatic castration-resistant prostate cancer (“mCRPC”)"

mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.

pik3ca medical

"VIKTORIA-1 PIK3CA mutant-type cohort"

PIK3CA is a gene that helps control cell growth and survival by sending signals inside cells; when it carries certain mutations, those signals can become stuck in the “on” position and drive cancer growth. For investors, PIK3CA matters because its mutations are a biomarker used to identify patients for targeted drugs and diagnostics, affecting clinical trial design, approval chances, and potential market size for therapies aimed at those mutations.

her2- medical

"human epidermal growth factor receptor 2 negative (“HER2-”)"

HER2- describes a tumor that lacks an excess of the HER2 protein or the gene that produces it; HER2 is a cell-surface receptor that can fuel cancer growth when overabundant. For investors, HER2- status matters because it determines whether patients will benefit from HER2-targeted medicines — like finding there is no matching lock for a specialized key — which directly affects the size of the eligible patient pool, treatment choices, pricing dynamics and potential sales for related drugs.

hr+ medical

"hormone receptor positive (“HR+”)"

Tumors labeled HR+ have cells that carry receptors for sex hormones (usually estrogen and/or progesterone), meaning the cancer can grow when those hormones bind to the receptors. Like a plant that thrives when it gets a certain light, HR+ cancers often respond to treatments that block or lower those hormones; for investors this affects which drugs, diagnostics, and clinical trials are relevant and influences market size, approval prospects, and revenue potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort

Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer

Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid oral presentation and three poster presentations will be featured at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2026 being held October 23-27, 2026, in Madrid, Spain. Data from its clinical trials of gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) locally advanced or metastatic breast cancer (“ABC”) and metastatic castration-resistant prostate cancer (“mCRPC”) will be presented.

Late Breaking Rapid Oral Presentation Details:

Title: VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients with HR+/HER2- advanced breast cancer (ABC) (Study 2)
Presentation Number: LBA 16
Speaker: Barbara Pistilli, MD
Session Title: Rapid oral 1: Breast cancer, advanced stage
Room: Almeria Auditorium - Hall 9
Date: Saturday, October 24, 2026
Time: 10:15 –11:45 a.m. CEST

Poster Presentation Details:

Title: A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presentation Number: 2237P
Presenting Author: Adam Sharp, MD, PhD
Session Title: Poster Display session, Metastatic prostate cancer
Date: Friday, October 23, 2026
Time: 3:15 p.m. – 4:00 p.m. CEST

Title: Gedatolisib (Ged) vs Other Regimens Post-CDK4/6i and Endocrine Therapy (ET) in PIK3CA Wild-Type (WT) HR+/ HER2- Advanced Breast Cancer (aBC): A Network Meta-Analysis (NMA)
Presentation Number: 1873P
Presenting Author: Sara Tolaney, MD
Session Title: Poster Display session, HR+ breast cancer
Date: Saturday, October 24, 2026
Time: 12:00 p.m. – 12:45 p.m. CEST

Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy (ET) and Palbociclib vs ET and Ribociclib as First-Line (1L) Treatment in Patients With HR-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (ABC) (VIKTORIA-2)
Presentation Number: 57TiP
Presenting Author: Giuseppe Curigliano, MD, PhD
Session Title: Poster Display session, Advanced breast cancer, other
Date: Saturday, October 24, 2026
Time: 12:00 p.m. – 12:45 p.m. CEST

Abstracts will be published online via the ESMO website at 12:05 a.m. CEST on October 19, 2026. The posters will be presented in the Poster Area – Hall 5. Electronic versions will also be available on the ESMO 2026 virtual platform.

About Celcuity
Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK™ (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

For Investors: 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com   
(763) 392-0123

For investors and media:
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924